BRPI0908292A2 - "métodos e composições para administração oral de exenatida" - Google Patents

"métodos e composições para administração oral de exenatida"

Info

Publication number: BRPI0908292A2
Authority: BR; Brazil
Prior art keywords: exenatide; compositions; methods; oral administration; oral
Prior art date: 2008-05-05

Application number

BRPI0908292-1A

Other languages

English (en)

Inventor

Kidron

Miriam

Original Assignee

Oramed Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-05

Filing date

2009-05-03

Publication date

2015-08-04

2009-05-03 Application filed by Oramed Ltd filed Critical Oramed Ltd

2015-08-04 Publication of BRPI0908292A2 publication Critical patent/BRPI0908292A2/pt

2022-09-20 Publication of BRPI0908292B1 publication Critical patent/BRPI0908292B1/pt

Links

HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 title 1
108010011459 Exenatide Proteins 0.000 title 1
229960001519 exenatide Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Zoology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Botany (AREA)
Cardiology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0908292-1A 2008-05-05 2009-05-03 Métodos e composições para administração oral de exenatida BRPI0908292B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US7153808P	2008-05-05	2008-05-05
US61/071,538		2008-05-05
PCT/IL2009/000461 WO2009136392A2 (en)	2008-05-05	2009-05-03	Methods and compositions for oral administration of exenatide

Publications (2)

Publication Number	Publication Date
BRPI0908292A2 true BRPI0908292A2 (pt)	2015-08-04
BRPI0908292B1 BRPI0908292B1 (pt)	2022-09-20

Family

ID=41265104

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0908292-1A BRPI0908292B1 (pt)	2008-05-05	2009-05-03	Métodos e composições para administração oral de exenatida

Country Status (15)

Country	Link
US (4)	US20110046053A1 (pt)
EP (2)	EP3275460A1 (pt)
JP (4)	JP2011519915A (pt)
CN (2)	CN102026646A (pt)
AU (1)	AU2009245294B2 (pt)
BR (1)	BRPI0908292B1 (pt)
CA (1)	CA2723434C (pt)
DK (1)	DK2300031T3 (pt)
ES (1)	ES2645588T3 (pt)
HK (1)	HK1223558A1 (pt)
NO (1)	NO2300031T3 (pt)
NZ (1)	NZ589390A (pt)
RU (1)	RU2566063C2 (pt)
WO (1)	WO2009136392A2 (pt)
ZA (1)	ZA201008090B (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007029238A2 (en) *	2005-09-06	2007-03-15	Oramed Pharmaceuticals, Inc.	Methods and compositions for oral administration of proteins
NZ588603A (en)	2008-03-26	2012-03-30	Oramed Ltd	Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
US20110046053A1 (en)	2008-05-05	2011-02-24	Oramed Ltd.	Methods and compositions for oral administration of exenatide
EP2461818B1 (en)	2009-08-03	2018-10-17	Incube Labs, Llc	Swallowable capsule and method for stimulating incretin production within the intestinal tract
CN102695545B (zh)	2009-09-08	2016-08-17	特色疗法股份有限公司	包括酶可剪切的酮改性的阿片样物质药物前体以及其可任选的抑制剂的组合物
US8759284B2 (en)	2009-12-24	2014-06-24	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20110262355A1 (en)	2010-04-21	2011-10-27	Jenkins Thomas E	Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US9259386B2 (en)	2010-12-23	2016-02-16	Rani Therapeutics, Llc	Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en)	2010-12-23	2014-08-19	Rani Therapeutics, Llc	Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en)	2010-12-23	2016-03-15	Rani Therapeutics, Llc	GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en)	2010-12-23	2020-05-05	Rani Therapeutics, Llc	Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en)	2010-12-23	2014-05-27	Rani Therapeutics, Llc	Device, system and methods for the oral delivery of therapeutic compounds
US8980822B2 (en)	2010-12-23	2015-03-17	Rani Therapeutics, Llc	Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en)	2010-12-23	2014-09-30	Rani Therapeutics, Llc	Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809271B2 (en)	2010-12-23	2014-08-19	Rani Therapeutics, Llc	Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en)	2010-12-23	2016-08-02	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8764733B2 (en)	2010-12-23	2014-07-01	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en)	2010-12-23	2016-08-02	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en)	2010-12-23	2016-03-15	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en)	2010-12-23	2018-01-09	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en)	2010-12-23	2016-08-16	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en)	2010-12-23	2015-03-03	Rani Therapeutics, Llc	Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9149617B2 (en)	2010-12-23	2015-10-06	Rani Therapeutics, Llc	Device, system and methods for the oral delivery of therapeutic compounds
US9629799B2 (en)	2010-12-23	2017-04-25	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2012205733B2 (en)	2011-01-11	2015-10-08	Signature Therapeutics, Inc.	Compositions comprising enzyme-cleavable oxycodone prodrug
US20120178813A1 (en)	2011-01-12	2012-07-12	Thetis Pharmaceuticals Llc	Lipid-lowering antidiabetic agent
EP2680859B1 (en)	2011-03-02	2022-04-27	Jerome Schentag	Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
PL2726091T3 (pl) *	2011-06-29	2020-08-10	Rani Therapeutics, Llc	Preparaty lecznicze dostarczane do kanału przewodu jelitowego za pomocą połykalnego urządzenia dostarczającego lek
EP3260131A1 (en) *	2012-01-03	2017-12-27	Oramed Ltd.	Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
CN113769074A (zh)	2012-02-01	2021-12-10	奥拉姆德有限公司	含有蛋白酶抑制物的组合物、包含前者的组合物和用于产生和使用前者的方法
US8765811B2 (en)	2012-07-10	2014-07-01	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
US9382187B2 (en)	2012-07-10	2016-07-05	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
ITFI20120259A1 (it) *	2012-11-27	2014-05-28	Stefano Bacci	Analoghi del glucagon-like peptide (glp-1) per uso topico.
WO2014106846A2 (en) *	2013-01-03	2014-07-10	Oramed Ltd.	Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
MX384232B (es)	2013-03-14	2025-03-14	Jerome J Schentag	Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.
EP2799062A1 (en) *	2013-05-03	2014-11-05	Gilberto Borges de Brito	Pharmaceutical product for inducing magnified release of endogenous gut hormones, pyy and glp-1, to a therapeutic effect on obesity and dm2
CA2947741A1 (en)	2014-05-05	2015-11-12	Thetis Pharmaceuticals Llc	Compositions and methods relating to ionic salts of peptides
US10220076B2 (en)	2014-05-15	2019-03-05	Incube Labs, Llc	Pharmaceutical compositions and methods for fabrication of solid masses comprising glucose regulating proteins
US9242008B2 (en)	2014-06-18	2016-01-26	Thetis Pharmaceuticals Llc	Mineral amino-acid complexes of fatty acids
US9999626B2 (en)	2014-06-18	2018-06-19	Thetis Pharmaceuticals Llc	Mineral amino-acid complexes of active agents
JP7211704B2 (ja)	2015-01-29	2023-01-24	ノヴォノルディスクアー／エス	Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
CN104740647A (zh) *	2015-04-08	2015-07-01	东莞市麦亘生物科技有限公司	一种艾塞那肽口服制剂及其制备方法
LT3297653T (lt)	2015-05-22	2022-01-10	The Board Of Trustees Of The Leland Stanford Junior University	Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
RU2702690C2 (ru) *	2015-08-13	2019-10-09	БИОЛИНГУС АйПи ЛЛСи	Способ получения продуктов, содержащих стабилизированные активные вещества, и композиций, содержащих таковые
US10653753B2 (en)	2016-03-04	2020-05-19	Eiger Biopharmaceuticals, Inc.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
ES2827796T3 (es)	2016-06-03	2021-05-24	Thetis Pharmaceuticals Llc	Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
LT3541366T (lt)	2016-11-21	2025-03-10	Amylyx Pharmaceuticals, Inc.	Eksendino (9-39) buferiniai preparatai
EP3965755A1 (en)	2019-05-06	2022-03-16	Evonik Operations GmbH	Preparation for use in weight management comprising omega-3 fatty acid salts and basic amino acids
CN112057619A (zh)	2019-06-10	2020-12-11	苏州兰鼎生物制药有限公司	一种具有降血糖作用的药物组合物
WO2021148990A1 (en) *	2020-01-23	2021-07-29	Axcess Limited	Cellular uptake
WO2021166899A1 (ja) *	2020-02-17	2021-08-26	宇部興産株式会社	インクレチン様物質と組み合わせて使用するための消化管プロテアーゼ阻害剤を含む薬剤
FR3120189B1 (fr)	2021-03-01	2024-11-29	Farid Bennis	Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
IL305493A (en)	2021-03-09	2023-10-01	Ensysce Biosciences Inc	Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof
CA3230025A1 (en)	2021-09-29	2023-04-06	Lynn Kirkpatrick	Enzyme-cleavable methadone prodrugs and methods of use thereof
WO2023249087A1 (ja) *	2022-06-24	2023-12-28	三生医薬株式会社	医薬組成物およびその製造方法
WO2025090920A1 (en) *	2023-10-25	2025-05-01	Piton Therapeutics, Inc.	Compositions and methods for treating dysfunction of glucose metabolism and/or regulation
WO2025122509A1 (en) *	2023-12-04	2025-06-12	Poviva Corp	Compositions and methods for treating diabetes

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL68769A (en)	1983-05-23	1986-02-28	Hadassah Med Org	Pharmaceutical compositions containing insulin for oral administration
JPS6350793A (ja)	1986-08-20	1988-03-03	株式会社東芝	高速増殖炉の崩壊熱除去システム
US5034415A (en)	1987-08-07	1991-07-23	Century Laboratories, Inc.	Treatment of diabetes mellitus
ES2045276T3 (es)	1988-07-21	1994-01-16	Hoffmann La Roche	Preparacion de insulina
JPH02250823A (ja) *	1989-03-24	1990-10-08	Tsumura & Co	マイクロカプセル剤およびその製造方法
GB9007052D0 (en)	1990-03-29	1990-05-30	Skua Investments Ltd	Pharmaceutical formulations
US5206219A (en) *	1991-11-25	1993-04-27	Applied Analytical Industries, Inc.	Oral compositions of proteinaceous medicaments
US6692766B1 (en) *	1994-06-15	2004-02-17	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Controlled release oral drug delivery system
US5824638A (en) *	1995-05-22	1998-10-20	Shire Laboratories, Inc.	Oral insulin delivery
IL114673A (en)	1995-07-19	2000-12-06	Hadasit Med Res Service	Pharmaceutical compositions containing protein for oral administration
JPH09208485A (ja) *	1996-01-31	1997-08-12	Teijin Ltd	ペプチド・蛋白質性薬物の水難溶性組成物
ATE493998T1 (de) *	1996-08-08	2011-01-15	Amylin Pharmaceuticals Inc	Pharmazeutische zusammensetzung mit einem exendin-4-peptid
JPH10330287A (ja) *	1997-03-31	1998-12-15	Nippon Suisan Kaisha Ltd	多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤
US5975893A (en)	1997-06-20	1999-11-02	Align Technology, Inc.	Method and system for incrementally moving teeth
JP2000050793A (ja) *	1998-08-07	2000-02-22	Meiji Milk Prod Co Ltd	人工乳組成物
JP2000128805A (ja)	1998-10-27	2000-05-09	Nippon Suisan Kaisha Ltd	多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤
US6761903B2 (en)	1999-06-30	2004-07-13	Lipocine, Inc.	Clear oil-containing pharmaceutical compositions containing a therapeutic agent
JP2001240558A (ja)	2000-02-29	2001-09-04	Nippon Suisan Kaisha Ltd	多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US6673574B2 (en)	2000-11-30	2004-01-06	Unigene Laboratories Inc.	Oral delivery of peptides using enzyme-cleavable membrane translocators
KR20010069322A (ko)	2001-03-08	2001-07-25	서종수	휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법
CN1160122C (zh)	2001-04-20	2004-08-04	清华大学	一种制备口服胰岛素油相制剂的方法
AU2002316717B8 (en)	2001-07-18	2005-09-29	Solae Holdings Llc	High protein, Bowman-Birk Inhibitor Concentrate and process for its manufacture
US20030198666A1 (en)	2002-01-07	2003-10-23	Richat Abbas	Oral insulin therapy
US7767828B2 (en)	2003-11-12	2010-08-03	Phenomix Corporation	Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
US20050143303A1 (en)	2003-12-26	2005-06-30	Nastech Pharmaceutical Company Inc.	Intranasal administration of glucose-regulating peptides
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
CA2563533C (en)	2004-04-15	2013-10-01	Shmuel A. Ben-Sasson	Compositions capable of facilitating penetration across a biological barrier
RU2527893C2 (ru)	2004-07-19	2014-09-10	Биокон Лимитед	Инсулин-олигомерные конъюгаты, их препараты и применения
WO2006025882A2 (en) *	2004-08-25	2006-03-09	The Uab Research Foundation	Absorption enhancers for drug administration
US20060046962A1 (en)	2004-08-25	2006-03-02	Aegis Therapeutics Llc	Absorption enhancers for drug administration
WO2007029238A2 (en)	2005-09-06	2007-03-15	Oramed Pharmaceuticals, Inc.	Methods and compositions for oral administration of proteins
US20070086972A1 (en)	2005-09-12	2007-04-19	Jacob Birnbaum	Hair growth compositions and methods for treating hair loss or related conditions
US20070077283A1 (en) *	2005-09-30	2007-04-05	Nastech Pharmaceutical Company Inc.	Method of enhancing transmucosal delivery of therapeutic compounds
CN101095942B (zh) *	2006-06-30	2011-11-16	北京民海生物科技有限公司	一种包含稳定剂的Exendin-4注射剂药物配方
NZ588603A (en)	2008-03-26	2012-03-30	Oramed Ltd	Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
US20110046053A1 (en)	2008-05-05	2011-02-24	Oramed Ltd.	Methods and compositions for oral administration of exenatide
CN102105159B (zh)	2008-06-17	2015-07-08	印第安纳大学研究及科技有限公司	基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
JP5740689B2 (ja)	2008-08-18	2015-06-24	エンテラバイオエルティーディー．	タンパク質の経口投与用の方法および組成物
EP3260131A1 (en)	2012-01-03	2017-12-27	Oramed Ltd.	Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
CN113769074A (zh)	2012-02-01	2021-12-10	奥拉姆德有限公司	含有蛋白酶抑制物的组合物、包含前者的组合物和用于产生和使用前者的方法
WO2014106846A2 (en)	2013-01-03	2014-07-10	Oramed Ltd.	Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof

2009
- 2009-05-03 US US12/990,097 patent/US20110046053A1/en not_active Abandoned
- 2009-05-03 JP JP2011508050A patent/JP2011519915A/ja active Pending
- 2009-05-03 AU AU2009245294A patent/AU2009245294B2/en active Active
- 2009-05-03 DK DK09742563.1T patent/DK2300031T3/en active
- 2009-05-03 CA CA2723434A patent/CA2723434C/en active Active
- 2009-05-03 BR BRPI0908292-1A patent/BRPI0908292B1/pt active IP Right Grant
- 2009-05-03 NO NO09742563A patent/NO2300031T3/no unknown
- 2009-05-03 NZ NZ589390A patent/NZ589390A/en unknown
- 2009-05-03 WO PCT/IL2009/000461 patent/WO2009136392A2/en not_active Ceased
- 2009-05-03 CN CN2009801162547A patent/CN102026646A/zh active Pending
- 2009-05-03 EP EP17185379.9A patent/EP3275460A1/en not_active Withdrawn
- 2009-05-03 ES ES09742563.1T patent/ES2645588T3/es active Active
- 2009-05-03 EP EP09742563.1A patent/EP2300031B1/en active Active
- 2009-05-03 RU RU2010146372/15A patent/RU2566063C2/ru active
- 2009-05-03 CN CN201511020513.XA patent/CN105903005A/zh active Pending
2010
- 2010-11-11 ZA ZA2010/08090A patent/ZA201008090B/en unknown
2013
- 2013-04-02 US US13/855,346 patent/US10350162B2/en active Active
2014
- 2014-09-05 JP JP2014181740A patent/JP6356548B2/ja active Active
2016
- 2016-08-12 JP JP2016158435A patent/JP6379143B2/ja active Active
- 2016-10-14 HK HK16111867.9A patent/HK1223558A1/zh unknown
2018
- 2018-03-28 JP JP2018063341A patent/JP2018115204A/ja active Pending
2019
- 2019-06-10 US US16/435,854 patent/US20190314275A1/en not_active Abandoned
2021
- 2021-04-29 US US17/243,660 patent/US20210322305A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ589390A (en)	2011-11-25
US20190314275A1 (en)	2019-10-17
JP2018115204A (ja)	2018-07-26
US20110046053A1 (en)	2011-02-24
DK2300031T3 (en)	2017-10-30
CN102026646A (zh)	2011-04-20
CN105903005A (zh)	2016-08-31
ZA201008090B (en)	2012-08-29
US20210322305A1 (en)	2021-10-21
EP2300031B1 (en)	2017-09-20
JP6356548B2 (ja)	2018-07-11
EP3275460A1 (en)	2018-01-31
EP2300031A2 (en)	2011-03-30
AU2009245294A1 (en)	2009-11-12
EP2300031A4 (en)	2012-10-24
CA2723434A1 (en)	2009-11-12
JP2017008080A (ja)	2017-01-12
CA2723434C (en)	2018-01-23
RU2566063C2 (ru)	2015-10-20
AU2009245294B2 (en)	2014-02-20
US10350162B2 (en)	2019-07-16
US20130195939A1 (en)	2013-08-01
NO2300031T3 (pt)	2018-02-17
ES2645588T3 (es)	2017-12-05
WO2009136392A2 (en)	2009-11-12
JP2011519915A (ja)	2011-07-14
WO2009136392A3 (en)	2010-03-11
JP6379143B2 (ja)	2018-08-22
JP2015038082A (ja)	2015-02-26
HK1223558A1 (zh)	2017-08-04
RU2010146372A (ru)	2012-06-20
BRPI0908292B1 (pt)	2022-09-20

Legal Events

Date	Code	Title	Description
2015-12-29	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-03-13	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2019-07-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-10-08	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-06-08	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-09-14	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
2021-09-21	B15G	Petition not considered as such [chapter 15.7 patent gazette]	Free format text: PETICAO NO 870210082766 DE 08/09/2021 NAO CONHECIDA EM VIRTUDE DO ART.219 (I) DA LPI, POIS FOI APRESENTADA FORA DO PRAZO (6.1 PUBLICADO NA RPI 2631 DE 08/06/2021; PRAZO DE 90 DIAS = 06/09/2021).
2022-04-05	B15V	Prolongation of time limit allowed
2022-05-17	B150	Others concerning applications: publication cancelled [chapter 15.30 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 15.7 NA RPI NO 2646 DE 21/09/2021 POR TER SIDO INDEVIDA.
2022-05-24	B11N	Dismissal: publication cancelled [chapter 11.14 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 11.2 NA RPI NO 2645 DE 14/09/2021 POR TER SIDO INDEVIDA.
2022-07-12	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-09-20	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/05/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

Publication	Publication Date	Title
BRPI0908292A2 (pt)	2015-08-04	"métodos e composições para administração oral de exenatida"
BRPI0907077A2 (pt)	2016-07-26	métodos e composições para administração oral de proteínas
CY2019010I1 (el)	2019-11-27	Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης
HRP20190100T1 (hr)	2019-04-05	Oralne formulacije analoga citidina i postupci za njihovu upotrebu
LTPA2018014I1 (lt)	2018-12-10	Farmacinė kompozicija 514
PT2542268T (pt)	2016-11-14	Composição sólida para administração oral de corantes e utilização desta
SMT201400181B (it)	2015-01-15	Composizioni per vasocostrizione e metodi d'uso
BRPI0914713A2 (pt)	2017-05-23	composição para cuidado oral
BRPI1011876A2 (pt)	2015-09-22	"composição farmacêutica estável e métodos de uso da mesma"
BRPI0808293A2 (pt)	2019-09-24	"composições para administração nasal"
PT2355851T (pt)	2018-05-23	Novos lípidos e composições para a administração de agentes terapêuticos
BRPI0913379A2 (pt)	2015-11-24	formulações farmacêuticas sólidas compreendendo bibw 2992
BRPI0812562A2 (pt)	2019-09-24	composições terapêuticas anti-cd20 e métodos
EP2316414A4 (en)	2011-09-21	HAIR CARE COMPOSITION
BRPI0810928A2 (pt)	2019-09-24	"composição farmacêutica"
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
LT2966175T (lt)	2019-08-26	Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
BRPI0914300A2 (pt)	2015-10-13	composições e métodos para imunogenicidade intensificada de somatostatina
BRPI0918206A2 (pt)	2015-12-08	derivados de animoéster e composição medicinal destes
PL2026747T3 (pl)	2016-07-29	Doustne kompozycje zapewniające polepszone usuwanie przebarwień nazębnych
EP2185112A4 (en)	2012-01-18	Stabilized therapeutic compositions and formulations
BRPI0913610A2 (pt)	2015-10-20	métodos e composições para tratamento bucal
BRPI1007484A2 (pt)	2016-02-16	composição farmacêutica para administração oral
BRPI0916486A2 (pt)	2016-02-16	composição para tratamento bucal
BRPI0909211A2 (pt)	2016-11-29	formulação orais e injetáveis de composto de tetraciclina